OPT101

Phase 2Small molecule

OOp-T LLC

OPT101 is one of 77 small molecule programs targeting Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaNot yet recruiting

Type 1 Diabetes MellitusActive, not recruiting

PneumoniaPhase 1

Not yet recruiting

Type 1 Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Retrovir

BBp Consulting, Inc

Preclinical

2 2

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 3

OPT101

OOp-T LLC

Phase 2

1 4

Pepcid

KKenvue Brands

Preclinical

1 5

Cancidas

FFresenius Kabi Taiwan Ltd.

Preclinical

1 6

Salbutamol

GSK

Preclinical

1 7

Foscavir

CClinigen, Inc.

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Angiotensin-Converting Enzyme Inhibitors

Boehringer Ingelheim

Preclinical

1 10

Combination Therapy

Chong Kun Dang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Type 1 Diabetes Mellitus

NCT06964087

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

Active, not recruiting·OOp-T LLC·Phase 2·NCT06964087·72 enrolled

Pneumonia1 trial

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Not yet recruiting·OOp-T LLC·Phase 1·NCT06669403·26 enrolled

ESS1 trial

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Completed·OOp-T LLC·Phase 1·NCT04589403·14 enrolled

Diabetes Mellitus, Type 11 trial

A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes

Completed·OOp-T LLC·Phase 1·NCT05428943·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for OPT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OPT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OPT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Op-T LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOp-T LLC

OPT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

Pneumonia1 trial

ESS1 trial

Diabetes Mellitus, Type 11 trial

References

Drug Info

Quick Facts

Related News